Business
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
NEWARK, CA / ACCESSWIRE / June 6, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that a late-breaking
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, CA / ACCESSWIRE / June 6, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (\"Protagonist\" or \"the Company\") today announced that a late-breaking abstract featuring blinded, randomized withdrawal data from the rusfertide (PTG-300) REVIVE Phase 2 study in polycythemia vera (PV) has been accepted for oral presentation at the European Hematology Association (EHA) 2023 Congress:Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera with the Hepcidin Mimetic, Rusfertide - Blinded Randomized Withdrawal Results of the REVIVE Study:- Late Breaking Oral Presentation: Presented by Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai on Sunday, June 11, 9:45 - 10:00 CESTAs previously announced, EHA will also feature two additional presentations from the Company's rusfertide peptide therapeutic development program, including new data and updates in polycythemia vera.Rusfertide (PTG-300) Improves (PV)-related Symptoms:- Presented by Andrew Kuykendall, MD, Moffitt Cancer Center on Friday, June 9, 18:00 - 19:00 CESTPharmacokinetic and Pharmacodynamic Effects of Rusfertide in Polycythemia Vera: Results from an Ongoing Phase 2 Study in Patients with Elevated Hematocrit Values:- Presented by Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai on Friday, June 9, 18:00 - 19:00 CEST\"We are very pleased to showcase a breadth of data at EHA demonstrating the tremendous promise for rusfertide to change the polycythemia vera treatment paradigm by potentially eliminating the need for phlebotomy, providing improvement of symptoms associated with PV, controlling erythrocytosis and ultimately achieving the treatment goal of maintaining hematocrit under 45% in step with current NCCN and ELN Clinical Practice Guidelines,\" said Arturo Molina, MD, MS, Chief Medical Officer, Protagonist Therapeutics.Molina continued, \"We look forward to connecting at this year's Congress with dedicated hematology-oncology researchers, patients and advocates as we work together to advance the hepcidin mimetic rusfertide as a selective erythrocytosis controlling agent that can potentially improve how a PV patient feels and functions.\"About ProtagonistProtagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinic...